Seborrheic Infantile Dermatitis

Categories: Skin diseases

Aliases & Classifications for Seborrheic Infantile Dermatitis

MalaCards integrated aliases for Seborrheic Infantile Dermatitis:

Name: Seborrheic Infantile Dermatitis 12 15 17
Cradle Cap 12 74
Generalized Seborrheic Dermatitis of Infants 12
Complement Component 5 Deficiency 74
Infantile Seborrhoeic Dermatitis 12
Infantile Seborrheic Dermatitis 12
Seborrhoeic Dermatitis of Scalp 12
Seborrheic Dermatitis of Scalp 74
Seborrhoeic Eczema of Scalp 12
Complement 5 Dysfunction 12
Seborrheic Dermatitis 74
Scurfiness of Scalp 74
Pityriasis Capitis 12
Seborrhoea Capitis 12
Seborrhea Capitis 12
Seborrhea Sicca 12
Dandruff 45


External Ids:

Disease Ontology 12 DOID:8941
ICD9CM 36 690.11
MeSH 45 D063807
ICD10 34 L21.0 L21.1

Summaries for Seborrheic Infantile Dermatitis

Disease Ontology : 12 A seborrheic dermatitis that involves fungal infection of the scalp of recently born babies caused by Malassezia furfur. It is occasionally linked to immune disorders. The symptoms include thick, crusty, yellow or brown scales over the child's scalp.

MalaCards based summary : Seborrheic Infantile Dermatitis, also known as cradle cap, is related to dermatitis and seborrheic dermatitis. An important gene associated with Seborrheic Infantile Dermatitis is TECR (Trans-2,3-Enoyl-CoA Reductase), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and JAK-STAT signaling pathway (KEGG). The drugs Isotretinoin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and ovary.

Related Diseases for Seborrheic Infantile Dermatitis

Diseases in the Seborrheic Dermatitis family:

Seborrheic Infantile Dermatitis

Diseases related to Seborrheic Infantile Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 42)
# Related Disease Score Top Affiliating Genes
1 dermatitis 10.4
2 seborrheic dermatitis 10.4
3 pyoderma 10.2
4 blepharitis 10.2
5 skin conditions 10.1
6 dermatitis, atopic 10.1
7 hypereosinophilic syndrome, idiopathic 10.0 IL3 IL5
8 atopic keratoconjunctivitis 10.0 IL3 IL5
9 neurofibromatosis, type ii 10.0
10 breast cancer 10.0
11 ige responsiveness, atopic 10.0
12 skin disease 10.0
13 contact dermatitis 10.0
14 psoriasis 10.0
15 charles bonnet syndrome 10.0
16 keratoconjunctivitis 10.0 IL3 IL5
17 intrinsic asthma 10.0 IL3 IL5
18 eosinophilic gastroenteritis 10.0 IL3 IL5
19 eosinophilic gastritis 10.0 IL3 IL5
20 pollen allergy 10.0 IL3 IL5
21 respiratory allergy 9.9 IL3 IL5
22 felty syndrome 9.9 CSF2 IL3
23 granulocytopenia 9.9 CSF2 IL3
24 cyclic neutropenia 9.9 CSF2 IL3
25 neutropenia 9.8 CSF2 IL3
26 anemia of prematurity 9.8 CSF2 IL3
27 thrombocytosis 9.8 CSF2 IL3
28 chronic tic disorder 9.8 CSF2 IL5
29 pancytopenia 9.8 CSF2 IL3
30 megakaryocytic leukemia 9.8 CSF2 IL3
31 severe congenital neutropenia 9.8 CSF2 IL3
32 bronchial disease 9.8 CSF2 IL5
33 diphtheria 9.7 CSF2 IL3
34 aspergillosis 9.7 CSF2 IL5
35 allergic hypersensitivity disease 9.7 IL3 IL5
36 sarcoidosis 1 9.7 CSF2 IL3
37 respiratory system disease 9.6 CSF2 IL5
38 eosinophilic pneumonia 9.5 CSF2 IL3 IL5
39 leukocyte disease 9.5 CSF2 IL3 IL5
40 hypereosinophilic syndrome 9.5 CSF2 IL3 IL5
41 asthma 9.5 CSF2 IL3 IL5
42 bone marrow cancer 9.5 CSF2 IL3

Comorbidity relations with Seborrheic Infantile Dermatitis via Phenotypic Disease Network (PDN):

Acute Cystitis

Graphical network of the top 20 diseases related to Seborrheic Infantile Dermatitis:

Diseases related to Seborrheic Infantile Dermatitis

Symptoms & Phenotypes for Seborrheic Infantile Dermatitis

Drugs & Therapeutics for Seborrheic Infantile Dermatitis

Drugs for Seborrheic Infantile Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Ciclopirox Approved, Investigational Phase 4,Phase 3 29342-05-0 2749
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Polyestradiol phosphate Approved Phase 4 28014-46-2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 6473866 445643 439492
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 65277-42-1 47576
Drospirenone Approved Phase 4 67392-87-4 68873
Norgestrel Approved Phase 4 6533-00-2 13109
Benzoyl peroxide Approved Phase 4,Phase 1,Phase 2 94-36-0 7187
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Desogestrel Approved Phase 4 54024-22-5 40973
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
17 Salicylates Phase 4
18 Analgesics Phase 4,Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Cyclooxygenase Inhibitors Phase 4
22 Dermatologic Agents Phase 4,Phase 2,Phase 1,Not Applicable
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1
25 Antifungal Agents Phase 4,Phase 3,Phase 2,Not Applicable
26 Antirheumatic Agents Phase 4,Phase 2,Phase 1
27 Keratolytic Agents Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 1
29 Emollients Phase 4,Not Applicable
30 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
32 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
33 Estradiol 3-benzoate Phase 4
34 Contraceptive Agents Phase 4,Phase 1,Phase 2
35 Estradiol 17 beta-cypionate Phase 4
36 Estrogens Phase 4
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2
40 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
41 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
42 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
43 insulin Phase 4
44 Vitamin B9 Phase 4
45 Drospirenone and ethinyl estradiol combination Phase 4
46 Vitamins Phase 4
47 Folate Phase 4
48 Vitamin B Complex Phase 4
49 Insulin, Globin Zinc Phase 4
50 Natriuretic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
2 Promiseb Topical Cream for Cradle Cap Completed NCT01214434 Phase 4
3 Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis Completed NCT01591070 Phase 4 Tacrolimus;Tacrolimus
5 Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis Completed NCT00824863 Phase 4 ketoconazole 2% foam
6 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
7 An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment Completed NCT01466673 Phase 4 Ethinyl estradiol/Norgestimate (EE/NGM);Ethinyl estradiol/Desogestrel (EE/DSG)
8 A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis Recruiting NCT03567980 Phase 4 Crisaborole
9 Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis Unknown status NCT01011621 Phase 3 0.5% prednisolone acetate cream;0.1% betamethasone valerate cream
10 Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis Completed NCT00565279 Phase 3 ASF1057;ASF1057
11 Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis Completed NCT02004860 Phase 3 Protopic (R);Mycoster (R)
12 Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp Completed NCT01137630 Phase 2, Phase 3 K40a;K40b;Placebo
13 K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp Completed NCT01137331 Phase 3 K301;Placebo
14 Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis Completed NCT00862654 Phase 3 clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week);clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week);clobetasol propionate shampoo (2/week);ketoconazole shampoo (2/week)
15 Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias Completed NCT00920140 Phase 2 GSK1120212;GSK1120212
16 Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag Completed NCT01147809 Phase 2 Eltrombopag olamine
17 Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) Completed NCT01520922 Phase 2 Bendamustine
18 Study Of Ispinesib In Subjects With Breast Cancer Completed NCT00089973 Phase 2 Ispinesib
19 A 4 Week Study of Elidel for the Treatment of Seborrheic Dermatitis Completed NCT00403559 Phase 2 Elidel
20 A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face Completed NCT00408330 Phase 2 Azelaic Acid 15% Gel;Inactive 15% gel base
21 A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis Completed NCT02749383 Phase 2 PAC-14028 cream 0.3%;PAC-14028 cream 1.0%;PAC-14028 cream vehicle
22 Safety and Efficacy Study in Subjects With Seborrheic Dermatitis Completed NCT01703793 Phase 2 Test Product 49778;Test Product 10156;Vehicle (placebo)
23 Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers Completed NCT01254162 Phase 2 MTC896 Gel
24 The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage Completed NCT00991198 Phase 2 Topical oxygen;Topical oxygen;placebo
25 Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis Recruiting NCT03688971 Phase 2 Omiganan;Ketoconazole;Placebo
26 Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne Recruiting NCT03076320 Phase 1, Phase 2
27 A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease Recruiting NCT03582137 Phase 2 Cannabidiol
28 PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma Not yet recruiting NCT03598816 Phase 2 Durvalumab;Tremelimumab
29 Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Unknown status NCT00767546 Phase 1 Botulinum toxin
30 A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients Completed NCT00927823 Phase 1 PF-04691502
31 Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Completed NCT01351935 Phase 1 AVL-292
32 Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma Recruiting NCT03422094 Phase 1
33 Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer Active, not recruiting NCT02848443 Phase 1 Trifluridine/tipiracil hydrochloride (S 95005);Oxaliplatin;Bevacizumab;Nivolumab
34 Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Suspended NCT02117336 Phase 1 P1446A-05
35 Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation Unknown status NCT01315951 Not Applicable
36 Evaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face Unknown status NCT01024374
37 HIV Indicator Diseases Across Europe Study Unknown status NCT01681706
38 Drug Utilization Study on the Prescribing Indications for Cyproterone Acetate and Ethinyl Estradiol in 5 European Countries Unknown status NCT02494297
39 HIV Indicator Diseases Survey Across Europe - UK Arm Unknown status NCT01196468
40 Neurobiology of the Scalp in Seborrheic Dermatitis Completed NCT02349854
41 HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis Completed NCT00830908 Not Applicable
42 Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis Completed NCT02656368 Not Applicable
43 Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo Completed NCT01203189 Not Applicable ketoconazole 2% foam;ketoconazole 2% shampoo
44 Furocyst - Poly Cystic Ovary Syndrome Study Completed NCT02703064 Not Applicable
45 An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses Completed NCT01736670 Not Applicable Triamcinolone Acetonide spray;Triamcinolone acetonide cream;Alcohol spray
46 Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases Completed NCT02349399 Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics
47 Minimal Residual Disease in Peripheral T-cell Lymphoma Recruiting NCT03297697
48 Comparison of Scalp Microbiome of the Psoriasis and Seborrheic Dermatitis Patients Recruiting NCT03807453
49 Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis Active, not recruiting NCT03114111 Not Applicable aminolevulinic acid (ALA);Placebo
50 To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC Not yet recruiting NCT03130829 Not Applicable

Search NIH Clinical Center for Seborrheic Infantile Dermatitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :

Cochrane evidence based reviews: dandruff

Genetic Tests for Seborrheic Infantile Dermatitis

Anatomical Context for Seborrheic Infantile Dermatitis

MalaCards organs/tissues related to Seborrheic Infantile Dermatitis:

Skin, Testes, Ovary, T Cells, B Cells, Bone, Bone Marrow

Publications for Seborrheic Infantile Dermatitis

Articles related to Seborrheic Infantile Dermatitis:

(show all 13)
# Title Authors Year
Interventions for infantile seborrhoeic dermatitis (including cradle cap). ( 30828791 )
Recurrent Vulvar Ulcers and "Cradle Cap" in a 2-Year-Old. ( 30322698 )
Cradle cap. ( 24986302 )
Topical, Non-Medicated LOYON(®) in Facilitating the Removal of Scaling in Infants and Children with Cradle Cap: a Proof-of-Concept Pilot Study. ( 25119137 )
A double-blind, placebo-controlled pilot study to estimate the efficacy and tolerability of a nonsteroidal cream for the treatment of cradle cap (seborrheic dermatitis). ( 23652893 )
Olive oil for cradle cap? ( 21121479 )
Clinical inquiries. What's the best treatment for cradle cap? ( 17343816 )
On top of cradle cap. ( 17824212 )
The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). ( 12622623 )
Infantile seborrheic dermatitis: an approach to cradle cap. ( 8477601 )
Cradle cap. ( 2138530 )
A new treatment for cradle cap. ( 13388073 )

Variations for Seborrheic Infantile Dermatitis

Expression for Seborrheic Infantile Dermatitis

Search GEO for disease gene expression data for Seborrheic Infantile Dermatitis.

Pathways for Seborrheic Infantile Dermatitis

GO Terms for Seborrheic Infantile Dermatitis

Biological processes related to Seborrheic Infantile Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.58 CSF2 IL3 IL5
2 immune response GO:0006955 9.5 CSF2 IL3 IL5
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 IL3 IL5
4 regulation of signaling receptor activity GO:0010469 9.43 CSF2 IL3 IL5
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.37 CSF2 IL3
6 cytokine-mediated signaling pathway GO:0019221 9.33 CSF2 IL3 IL5
7 MAPK cascade GO:0000165 9.13 CSF2 IL3 IL5
8 positive regulation of podosome assembly GO:0071803 8.62 CSF2 IL5

Molecular functions related to Seborrheic Infantile Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.13 CSF2 IL3 IL5
2 growth factor activity GO:0008083 8.8 CSF2 IL3 IL5

Sources for Seborrheic Infantile Dermatitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
33 HPO
34 ICD10
35 ICD10 via Orphanet
39 LifeMap
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
56 Novoseek
59 OMIM via Orphanet
63 PubMed
71 SNOMED-CT via Orphanet
73 Tocris
75 UMLS via Orphanet
Loading form....